CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW
Cardio Diagnostics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.64−0.05 (-2.96%)
Close on Oct 19, 2026
- Market cap
- $4.85M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.65 (−61.73%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Cardio Diagnostics Holdings, Inc. saw revenue fall 57.5% to $14.83K over the twelve months to Dec 31, 2025. Free cash flow was -$5.91M.
Revenue
$14.83K
-57.5% vs. a year earlier
Operating income
-$6.48M
TTM Q4 2025
Free cash flow
-$5.91M
TTM Q4 2025
EPS, diluted
-$3.71
TTM Q4 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.85M
- P/E ratio
- –
- Price to sales
- 327.39
- Price to book
- 0.65
- Dividend yield
- –
- Free cash flow yield
- -121.85%
Fundamentals
- Revenue
- $14.83K
- Net income
- -$6.50M
- EPS, diluted
- -$3.71
- Free cash flow
- -$5.91M
- Book value per share
- $2.51
- Diluted shares
- 3M
Six years at a glance
Fiscal years 2020 to 2025, USD
Revenue
$14.83K-57.5% YoY
Operating income
-$6.48M
Net income
-$6.50M
EPS, diluted
-$3.71
Free cash flow
-$5.91M
Reported period